PERCEPTIVE ADVISORS LLC — 13F Holdings & Portfolio

CIK 1224962 · latest 13F-HR filed 2026-08-14

PERCEPTIVE ADVISORS LLC manages $6.66B in 13F-reported U.S. long-equity assets across 109 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are PRAX (10.23%), SYRE (5.76%), CELC (5.02%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 23 new positions and exited 13; 46 existing positions rose in reported value and 23 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$6.66B

Long-equity book

Holdings
109

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+23 / −13 / ↑46 / ↓23

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 48.9%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Jul 13, 2026.

Assets Under Management
$11.77B
Discretionary
$11.77B
Employees
49
Accounts
26
Address
51 ASTOR PLACE
10TH FLR
NEW YORK, NY 10003
Phone
(646) 205-5300
This firm reports 5 disclosure items on its registration.
Name Title / Status Ownership Type
COHN, SHMUEL, MORDECHAI ControlCHIEF FINANCIAL OFFICER
since Jul 2026
Less than 5%Individual
EDELMAN, JOSEPH, ERIC ControlCHIEF EXECUTIVE OFFICER AND PORTFOLIO MANAGER
since Dec 2000
75% or moreIndividual
MANNIX, JAMES, HENRY ControlCHIEF OPERATING OFFICER
since Dec 2006
Less than 5%Individual
RAKITIN, ALEXANDER, NMN ControlCHIEF COMPLIANCE OFFICER
since Oct 2017
Less than 5%Individual
ROSNER, MARCEL, TREBOUX ControlGENERAL COUNSEL
since Feb 2025
Less than 5%Individual
STONE, ADAM, LEO ControlCHIEF INVESTMENT OFFICER
since Dec 2025
10–25%Individual
Ownership & leadership changes · 5 filings with changes since Mar 30, 2012

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Jul 13, 2026 filing
  • No longer listedFIERRO, PETER, WILLIAM · CHIEF FINANCIAL OFFICER · Less than 5% · control person · listed since Jul 2007
  • ChangedCOHN, SHMUEL, MORDECHAI · title CHIEF FINANCIAL OFFICER - CREDIT & VENTURE → CHIEF FINANCIAL OFFICER
Mar 30, 2026 filing
  • AddedCOHN, SHMUEL, MORDECHAI · CHIEF FINANCIAL OFFICER - CREDIT & VENTURE · Less than 5% · control person
  • AddedSTONE, ADAM, LEO · CHIEF INVESTMENT OFFICER · 10–25% · control person
Mar 26, 2025 filing
  • AddedROSNER, MARCEL, TREBOUX · GENERAL COUNSEL · Less than 5% · control person
Oct 23, 2017 filing
  • AddedRAKITIN, ALEXANDER, NMN · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
  • ChangedMANNIX, JAMES, HENRY · title CHIEF OPERATING OFFICER AND CHIEF COMPLIANCE OFFICER → CHIEF OPERATING OFFICER
Mar 30, 2016 filing
  • ChangedEDELMAN, JOSEPH, ERIC · title CEO → CHIEF EXECUTIVE OFFICER AND PORTFOLIO MANAGER
  • ChangedFIERRO, PETER, WILLIAM · title CFO → CHIEF FINANCIAL OFFICER
  • ChangedMANNIX, JAMES, HENRY · title CHIEF COMPLIANCE OFFICER → CHIEF OPERATING OFFICER AND CHIEF COMPLIANCE OFFICER
Mar 30, 2012 filing (earliest on record)
  • ListedEDELMAN, JOSEPH, ERIC · CEO · 75% or more · control person
  • ListedFIERRO, PETER, WILLIAM · CFO · Less than 5% · control person
  • ListedMANNIX, JAMES, HENRY · CHIEF COMPLIANCE OFFICER · Less than 5% · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

PERCEPTIVE ADVISORS LLC Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 PRAXIS PRECISION MEDICINES I PRAX 74006W207 $681.6M 10.23% 2,035,986 SH
2 SPYRE THERAPEUTICS INC SYRE 00773J202 $383.5M 5.76% 4,319,496 SH
3 CELCUITY INC CELC 15102K100 $334.5M 5.02% 3,197,200 SH
4 ASCENDIS PHARMA A/S ASND K08588103 $310.4M 4.66% 1,163,721 SH
5 RHYTHM PHARMACEUTICALS INC RYTM 76243J105 $287.2M 4.31% 2,586,295 SH
6 ROIVANT SCIENCES LTD ROIV G76279101 $286.1M 4.30% 8,085,461 SH
7 RELAY THERAPEUTICS INC RLAY 75943R102 $263.9M 3.96% 14,106,187 SH
8 TRAVERE THERAPEUTICS INC TVTX 89422G107 $213.2M 3.20% 3,752,574 SH
9 KARDIGAN INC KARD 485925101 $195.6M 2.94% 8,200,662 SH
10 NUVALENT INC NUVL 670703107 $195.2M 2.93% 1,580,505 SH
11 EDGEWISE THERAPEUTICS INC EWTX 28036F105 $177.7M 2.67% 4,373,974 SH
12 APOGEE THERAPEUTICS INC APGE 03770N101 $173.6M 2.61% 1,308,113 SH
13 AMYLYX PHARMACEUTICALS INC AMLX 03237H101 $149.7M 2.25% 8,334,882 SH
14 MEIRAGTX HLDGS PLC MGTX G59665102 $145.7M 2.19% 10,786,658 SH
15 ORUKA THERAPEUTICS INC ORKA 687604108 $128.0M 1.92% 1,345,063 SH
16 INHIBRX BIOSCIENCES INC INBX 45720N103 $123.0M 1.85% 1,297,763 SH
17 PROTAGONIST THERAPEUTICS INC PTGX 74366E102 $120.4M 1.81% 981,879 SH
18 SOLID BIOSCIENCES INC SLDB 83422E204 $118.9M 1.79% 11,906,646 SH
19 ZYMEWORKS INC ZYME 98985Y108 $109.3M 1.64% 4,182,953 SH
20 TANGO THERAPEUTICS INC TNGX 87583X109 $105.6M 1.58% 3,377,000 SH
21 IMMATICS N.V IMTX N44445109 $105.2M 1.58% 10,383,456 SH
22 NURIX THERAPEUTICS INC NRIX 67080M103 $104.8M 1.57% 4,320,422 SH
23 BIOCRYST PHARMACEUTICALS INC BCRX 09058V103 $103.1M 1.55% 10,308,888 SH
24 REVOLUTION MEDICINES INC RVMD 76155X100 $98.8M 1.48% 527,600 SH
25 AVALYN PHARMACEUTICALS INC AVLN 05348Y105 $88.1M 1.32% 2,675,296 SH
26 MODERNA INC Put MRNA 60770K107 $70.0M 1.05% 1,000,000 SH
27 DYNE THERAPEUTICS INC DYN 26818M108 $59.7M 0.90% 2,689,235 SH
28 BIOGEN INC BIIB 09062X103 $59.7M 0.90% 276,173 SH
29 IMMUNOVANT INC IMVT 45258J102 $52.3M 0.79% 1,357,383 SH
30 UNITEDHEALTH GROUP INC UNH 91324P102 $48.5M 0.73% 116,806 SH
31 SPDR SERIES TRUST Put XBI 78464A870 $47.5M 0.71% 300,000 SH
32 IONIS PHARMACEUTICALS INC IONS 462222100 $44.9M 0.67% 566,000 SH
33 SUTRO BIOPHARMA INC STRO 869367201 $43.3M 0.65% 1,304,846 SH
34 ALTO NEUROSCIENCE INC ANRO 02157Q109 $42.5M 0.64% 1,609,893 SH
35 JAZZ PHARMACEUTICALS PLC JAZZ G50871105 $41.0M 0.61% 170,000 SH
36 CORVUS PHARMACEUTICALS INC CRVS 221015100 $39.9M 0.60% 2,667,441 SH
37 SIONNA THERAPEUTICS INC SION 829401108 $39.8M 0.60% 905,000 SH
38 CYTOMX THERAPEUTICS INC. CTMX 23284F105 $39.1M 0.59% 10,439,185 SH
39 ARTIVION INC AORT 228903100 $39.0M 0.59% 1,737,290 SH
40 X4 PHARMACEUTICALS INC XFOR 98420X202 $37.0M 0.56% 7,933,491 SH
41 CORCEPT THERAPEUTICS INC CORT 218352102 $34.6M 0.52% 398,385 SH
42 REPLIGEN CORP RGEN 759916109 $33.9M 0.51% 248,212 SH
43 ANTERIS TECHNOLOGIES GLOBAL AVR 03675P102 $33.7M 0.51% 3,425,476 SH
44 RAPPORT THERAPEUTICS INC RAPP 75383L102 $32.2M 0.48% 773,342 SH
45 DAMORA THERAPEUTICS INC DMRA 36322Q206 $31.8M 0.48% 1,223,000 SH
46 CHARLES RIV LABS INTL INC CRL 159864107 $31.8M 0.48% 140,000 SH
47 AXSOME THERAPEUTICS INC. AXSM 05464T104 $29.0M 0.44% 118,450 SH
48 EYEPOINT INC Put EYPT 30233G209 $28.6M 0.43% 2,000,000 SH
49 DBV TECHNOLOGIES S A DBVT 23306J309 $27.1M 0.41% 1,653,350 SH
50 IRHYTHM HOLDINGS INC IRTC 450056106 $26.6M 0.40% 223,766 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $6.66B 109 0001012975-26-000777
2026-03-31 2026-05-15 $5.11B 94 0001012975-26-000443
2026-03-31 2026-05-29 $5.12B 94 0001012975-26-000499
2025-12-31 2026-02-17 $5.61B 116 0001012975-26-000155
2025-09-30 2025-11-14 $3.46B 93 0001012975-25-000762
Filer Information
Address
51 ASTOR PLACE, 10TH FLOOR
NEW YORK, NY 10003
Phone
(646) 205-5300
Filing Manager
PERCEPTIVE ADVISORS LLC
NEW YORK, NY
Signatory
Joseph Edelman
Managing Member